SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Meyers PA, Heller G, Healey JH, et al. Osteogenic sarcoma with clinically detectable metastasis at initial presentation. J Clin Oncol. 1993; 11: 449453.
  • 2
    Kager L, Zoubek A, Potschger U, et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2003; 21: 20112018.
  • 3
    Meyer WH, Pratt CB, Poquette CA, et al. Carboplatin/ifosfamide window therapy for osteosarcoma: results of the St Jude Children's Research Hospital OS-91 trial. J Clin Oncol. 2001; 19: 171182.
  • 4
    Harris MB, Gieser P, Goorin AM, et al. Treatment of metastatic osteosarcoma at diagnosis: a Pediatric Oncology Group study. J Clin Oncol. 1998; 16: 36413648.
  • 5
    Longhi A, Fabbri N, Donati D, et al. Neoadjuvant chemotherapy for patients with synchronous multifocal osteosarcoma: results in eleven cases. J Chemother. 2001; 13: 324330.
  • 6
    Bacci G, Briccoli A, Rocca M, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide. Ann Oncol. 2003; 14: 11261134.
  • 7
    Goorin AM, Harris MB, Bernstein M, et al. Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic ostesarcoma: a Pediatric Oncology Group trial. JClin Oncol. 2002; 20: 426433.
  • 8
    Mialou V, Philip T, Kalifa C, et al. Metastatic osteosarcoma at diagnosis: prognostic factors and long-term outcome-the French Pediatric Experience. Cancer 2005; 104: 11001109.
  • 9
    Harris MB, Cantor AB, Goorin AM, et al. Treatment of osteosarcoma with ifosfamide: comparison of response in pediatric patients with recurrent disease versus patients previously untreated—a Pediatric Oncology Group study. Med Pediatr Oncol. 1995; 24: 8792.
  • 10
    Horowitz ME, Etcubanas E, Christensen ML, et al. Phase II testing of melphalan in children with newly diagnosed rhabdomyosarcoma: a model for anticancer drug development. J Clin Oncol. 1988; 6: 308314.
  • 11
    Castleberry RP, Canor AB, Green AA, et al. Phase II investigational window using carboplatin, iproplatin, ifosfamide, and epirubicin in children with untreated disseminated neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol. 1994; 12: 16161620.
  • 12
    Meyer WH, Houghton PJ, Horowitz ME, et al. Use of investigational drugs as initial therapy for childhood solid tumors. Haematol Blood Transfers. 1989; 32: 141148.
  • 13
    Pappo AS, Etcubanas E, Santana VM, et al. A phase II trial of ifosfamide in previously untreated children and adolescents with unresectable rhabdomyosarcoma. Cancer 1993; 71: 21192125.
  • 14
    Ferguson WS, Harris MB, Goorin AM, et al. Presurgical window of carboplatin and surgery and multidrug chemotherapy for the treatment of newly diagnosed metastatic or unresectable osteosarcoma: Pediatric Oncology Group trial. J Pediatr Hematol Oncol. 2001; 23: 340348.
  • 15
    Smith M, Anderson B. Phase II window studies: 10 years of experience and counting. J Pediatr Hematol Oncol. 2001; 23: 334337.
  • 16
    Houghton P, Cheshire P, Myers L, et al. Evaluation of 9-dimethylaminomethyl-10-hydroxy camptothecin against xenografts derived from adult and childhood tumors. Cancer Chemother Pharmacol. 1992; 31: 229239.
  • 17
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc. 1958; 53: 457481.
  • 18
    Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York: John Wiley & Sons; 1980.
  • 19
    Huvos AG, Rosen G, Marcove RC. Primary osteogenic sarcoma. Pathologic aspects in 20 patients after treatment with chemotherapy, en bloc resection and prosthetic bone replacement. Arch Pathol Lab Med. 1977; 101: 1418.
  • 20
    Tubergen DG, Stewart CF, Pratt CB, et al. Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a Pediatric Oncology Group study. J Pediatr Hematol Oncol. 1996; 18: 352361.
  • 21
    Saltz L. Sirott M, Young C, et al. Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor. J Natl Cancer Inst. 1993; 85: 1499507.
  • 22
    Rowinsky EK, Grochow LB, Sartorius SE, et al. Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors. J Clin Oncol. 1996; 14: 122435.
  • 23
    Stewart C, Zamboni W, Crom W, et al. Topoisomerase I interactive drugs in children with Cancer. Invest New Drugs 1996; 14: 3747.
  • 24
    Santana VM, Zamboni WC, Kirstein MN, et al. A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors. Clin Cancer Res. 2003; 9: 633640.
  • 25
    Van Winkle P, Angiolillo A, Krailo M, et al. Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children's Cancer Group (CCG) experience. Pediatr Blood Cancer 2005; 44: 338347.